Physician profile

Amy Suzanne Mabry

Pediatric Hematology-Oncology · Glendale, AZ

NPI 1861032773

$666.69

in general payments reported to CMS, 2019-2025

8 companies · $36.42 in 2025

The $36.42 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).

See the full distribution for Pediatric Hematology-Oncology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$36.42

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Incyte Corporation $326.45 2021
Jazz Pharmaceuticals INC. $123.23 2021
Daiichi Sankyo INC. $70.99 2021
Genzyme Corporation $48.09 2021
Medline Industries LP $36.42 2025
Merck Sharp & Dohme LLC $23.86 2021
Ipsen Biopharmaceuticals, INC $19.66 2021
Chiesi USA, INC. $17.99 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amy Suzanne Mabry

$666.69

in general payments reported 2019-2025

Years
2021-2025
Top company
Incyte Corporation
Context
The $36.42 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).

https://glasscript.com/doctor/8421005/amy-suzanne-mabry

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.